Pharmacotherapy for hospital-acquired pneumonia

Bibliography

• Mehta RM, Niedermann MS. Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J Inten Care Med 2003;18:175
   PubMedGoogle Scholar
• Valle´s J, Pobo A, Garcia-Esquirol O, et al. Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset. Intensive Care Med 2007;33:1363-8
   PubMed Web of Science ®Google Scholar
• Torres A, Ewig S, Lode H, et al. Defining, treating and preventing hospital acquired pneumonia: european perspective. Intensive Care Med 2009;35:9-29
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22(5):387-94
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
   PubMed Web of Science ®Google Scholar
• Ewig S, Welte T, Torres A. Is healthcare-associated pneumonia a distinct entity needing specific therapy? Curr Opin Infect Dis 2012;25(2):166-75
   PubMedGoogle Scholar
• Koulenti D, Lisboa T, Brun-Buisson C, et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009;37:2360-8
   PubMed Web of Science ®Google Scholar
• Afshari A, Schrenzel J, Ieven M, Harbarth S. Rapid molecular diagnostics for bloodstream infection: a new frontier? Crit Care 2012;16:222
   PubMed Web of Science ®Google Scholar
• Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010;51(S1):S48-S53
   Google Scholar
• Jones RN. Microbial etiologies of hospital acquired bacterial pneumonia and ventilator-associated bacterial pneumonia program. Clin Infect Dis 2010;51(S1):S81-7
   PubMedGoogle Scholar
• Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther 2012;34(1):124-37
   PubMed Web of Science ®Google Scholar
• Daubin C, Vincent S, Vabret A, et al. Nosocomial viral ventilator-associated pneumonia in the intensive care unit: a prospective cohort study. Intensive Care Med 2005;31(8):1116-22
   PubMedGoogle Scholar
• Li Bassi G, Torres A. Ventilator-associated pneumonia: role of positioning. Curr Opin Crit Care 2011;17(1):57-63
   PubMed Web of Science ®Google Scholar
• Rello J, Ulldemolins M, Lisboa T, et al. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 2011;37:1332-9
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K.pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010;50:364-73
   PubMed Web of Science ®Google Scholar
• Afshari A, Pagani L, Harbarth S. Year in review 2011: critical care – infection. Crit Care 2012;16:242
   Google Scholar
• Biswas S, Brunel JM, Dubus JC, et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 2012;10:917-34
   PubMed Web of Science ®Google Scholar
• Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? Clin Infect Dis 2012;54:1720-6
   PubMed Web of Science ®Google Scholar
• Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012;39:105-14
   PubMed Web of Science ®Google Scholar
• Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013;57(8):3738-45
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57(3):349-58
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011;53:879-84
   PubMed Web of Science ®Google Scholar
• Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128(6):3854-62; Erratum in: Chest. 2006 Mar; 129(3): 831
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54:621-9
   PubMed Web of Science ®Google Scholar
• Duszyńska W. Pharmacokinetic- pharmacodynamic modelling of antibiotic therapy in severe sepsis. Anaesthesiol Intensive Ther 2012;44(3):158-64
   PubMedGoogle Scholar
• Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011;15:R206.2-17
   Google Scholar
• Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended–infusion dosing strategy. Clin Infect Dis 2007;44:357-63
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Sermaides GJ, Michalopoulous A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2005;5:581-9
   PubMed Web of Science ®Google Scholar
• Duszynska W, Taccone FS, Switala M, et al. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs. Int J Antimicrob Agents 2012;39:153-8
   PubMed Web of Science ®Google Scholar
• Craven DE, Chroneou A. Nosocomial pneumonia. In: Madell GL, Benett JE, Dolin R, editors, Principles and practice of infectious diseases. 7th edition. Elsevier Churchill Livingstone, Philadelphia; 2009. p. 3717-24
   Google Scholar
• Jean SS, Hsueh PR. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother 2011;12(14):2145-8
   PubMed Web of Science ®Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in us intensive care units: implications for fluoroquinolone use. JAMA 2003;289(7):885-8
   PubMed Web of Science ®Google Scholar
• Lepper PM, Grusa E, Reichl H, et al. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002;46(9):2920-5
   PubMed Web of Science ®Google Scholar
• Aarts MA, Hancock JN, Heyland D, et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008;36(1):108-17
   PubMed Web of Science ®Google Scholar
• Heyland DK, Dodek P, Muscedere J, et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008;36:737-44
   PubMed Web of Science ®Google Scholar
• Kumar A, Zarychanski R, Light B, et al.; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010;38:1773-85
   PubMed Web of Science ®Google Scholar
• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012;25:450-70
   PubMed Web of Science ®Google Scholar
• Fowler RA, Flavin KE, Barr J, et al. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003;123:835-44
   PubMed Web of Science ®Google Scholar
• Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009;66(5):1343-8
   PubMedGoogle Scholar
• Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006;129:1210-18
   PubMed Web of Science ®Google Scholar
• Singh N, Rogers P, Atwood CHW, et al. Short course empiric therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 2000;162:505-11
   PubMed Web of Science ®Google Scholar
• Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator- associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-98
   PubMed Web of Science ®Google Scholar
• Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2011;CD007577
   Google Scholar
• Wood GC. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2011;9:993-1000
   PubMed Web of Science ®Google Scholar
• Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilator- associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;184:106-15
   PubMed Web of Science ®Google Scholar
• Lu Q, Luo R, Bodin L, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012;117:1335-47
   PubMed Web of Science ®Google Scholar
• Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012;54(5):670-80
   PubMed Web of Science ®Google Scholar
• Arnold HM, Sawyer AM, Kollef MH. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 2012;57:1226-33
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008;102(3):407-12
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9
   PubMed Web of Science ®Google Scholar
• Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007;60(6):1216-26
   PubMed Web of Science ®Google Scholar
• Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999;14:218-20
   PubMed Web of Science ®Google Scholar
• Patel GP, Balk RA. Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med 2012;185(2):133-9
   PubMedGoogle Scholar
• Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24
   PubMed Web of Science ®Google Scholar
• Annane D, Sebille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006;34:22-30
   PubMed Web of Science ®Google Scholar
• De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multi- center study. JAMA 2002;288:2859-67
   PubMed Web of Science ®Google Scholar
• Sahm D. The in vitro activity of doripenem. Clin Infect Dis 2009;49(Suppl 1):S11-16; in this supplement
   Google Scholar
• Mandell L. Doripenem: a new carbapenem in the treatment of nosocomial infection. Clin Infect Dis 2009;49(Suppl 1):S1-3
   PubMedGoogle Scholar
• Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089
   PubMed Web of Science ®Google Scholar
• Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012;16(6):R218
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013;41(2):489-95
   PubMed Web of Science ®Google Scholar
• Liapikou A, Fernandez L, Torres A; Clinical Investigation. Telavancin in the treatment of nosocomial pneumonia: review of the clinical evidence. Future Sci 2012;2(9):939-48
   Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52:31-40
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm358209.htm
   Google Scholar
• Basilea Pharmaceutica Ltd. Basilea announces positive top-line data from phase III study of ceftobiprole in hospital-acquired pneumonia [press release]. Basilea Pharmaceutica Ltd, Basel, Switzerland; 2007. Available from: http://www.basilea.com/News-and-Media/Basilea-Announces-Positive-Top-line-Data-from-Phase-III-Study-of-Ceftobiprole-in-Hospital-Acquired-Pneumonia/144 [Accessed 19 March 2010]
   Google Scholar
• Lagacé-Wiens PR, Rubinstein E. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia. Expert Opin Drug Metab Toxicol 2013;9(6):789-99
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390-4
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/show/NCT01808092?term=avibactam&rank=11
   Google Scholar
• Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008;46:1157-64
   PubMed Web of Science ®Google Scholar
• Francois B, Luyt CE, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012;40:2320-6
   PubMed Web of Science ®Google Scholar
• Rello J, Chastre J, Cornaglia G, Masterton R, VAP Care Bundles Contributors. A European care bundle for management of ventilator-associated pneumonia. J Crit Care 2010;36(5):773-80
   Google Scholar
• Ferrer M, Liapikou A, Valencia M, et al. Validation of the American Thoracic Society–Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. Clin Infect Dis 2010;50:945-52
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Deja M, Koulenti D, et al.; EU-VAP Study Investigators. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 2013;39(4):672-81
   PubMed Web of Science ®Google Scholar
• Kett DH, Cano E, Quartin AA, et al.; and the Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP). Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011;11:181-9
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Antimicrobial management strategies for gram-positive bacterial resistance in the intensive care unit. Crit Care Med 2001;29:100-7
   PubMed Web of Science ®Google Scholar
• Paladino JA, Sunderlin JL, Forrest A, Schentag JJ. Characterization of the onset and consequences of pneumonia due to fluoroquinolone- susceptible or -resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003;52:457-63
   PubMed Web of Science ®Google Scholar